Equities

Exicure Inc

Exicure Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)10.86
  • Today's Change-0.33 / -2.95%
  • Shares traded1.02m
  • 1 Year change+339.68%
  • Beta1.6648
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments0.828.5839
Total Receivables, Net0.02--0
Total Inventory------
Prepaid expenses0.770.623.25
Other current assets, total0.430.851.28
Total current assets2.021044
Property, plant & equipment, net6.579.7912
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets00.049.33
Total assets122365
LIABILITIES
Accounts payable1.630.363.41
Accrued expenses0.881.286.46
Notes payable/short-term debt000
Current portion long-term debt/capital leases--06.87
Other current liabilities, total--017
Total current liabilities2.511.6434
Total long term debt000
Total debt006.87
Deferred income tax------
Minority interest------
Other liabilities, total6.046.7720
Total liabilities8.558.4154
SHAREHOLDERS EQUITY
Common stock0.000.000.01
Additional paid-in capital193188181
Retained earnings (accumulated deficit)(190)(173)(170)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total00.000.00
Total equity3.031511
Total liabilities & shareholders' equity122365
Total common shares outstanding1.730.990.73
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.